PT3227277T - Composto antimicótico - Google Patents
Composto antimicóticoInfo
- Publication number
- PT3227277T PT3227277T PT158087700T PT15808770T PT3227277T PT 3227277 T PT3227277 T PT 3227277T PT 158087700 T PT158087700 T PT 158087700T PT 15808770 T PT15808770 T PT 15808770T PT 3227277 T PT3227277 T PT 3227277T
- Authority
- PT
- Portugal
- Prior art keywords
- antimycotic compound
- antimycotic
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- G—PHYSICS
- G06—COMPUTING OR CALCULATING; COUNTING
- G06F—ELECTRIC DIGITAL DATA PROCESSING
- G06F1/00—Details not covered by groups G06F3/00 - G06F13/00 and G06F21/00
- G06F1/26—Power supply means, e.g. regulation thereof
- G06F1/32—Means for saving power
- G06F1/3203—Power management, i.e. event-based initiation of a power-saving mode
- G06F1/3234—Power saving characterised by the action undertaken
- G06F1/325—Power saving in peripheral device
- G06F1/3268—Power saving in hard disk drive
-
- G—PHYSICS
- G11—INFORMATION STORAGE
- G11C—STATIC STORES
- G11C11/00—Digital stores characterised by the use of particular electric or magnetic storage elements; Storage elements therefor
- G11C11/21—Digital stores characterised by the use of particular electric or magnetic storage elements; Storage elements therefor using electric elements
- G11C11/34—Digital stores characterised by the use of particular electric or magnetic storage elements; Storage elements therefor using electric elements using semiconductor devices
- G11C11/40—Digital stores characterised by the use of particular electric or magnetic storage elements; Storage elements therefor using electric elements using semiconductor devices using transistors
- G11C11/401—Digital stores characterised by the use of particular electric or magnetic storage elements; Storage elements therefor using electric elements using semiconductor devices using transistors forming cells needing refreshing or charge regeneration, i.e. dynamic cells
- G11C11/4063—Auxiliary circuits, e.g. for addressing, decoding, driving, writing, sensing or timing
- G11C11/407—Auxiliary circuits, e.g. for addressing, decoding, driving, writing, sensing or timing for memory cells of the field-effect type
- G11C11/4074—Power supply or voltage generation circuits, e.g. bias voltage generators, substrate voltage generators, back-up power, power control circuits
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Theoretical Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microelectronics & Electronic Packaging (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- General Physics & Mathematics (AREA)
- Computer Hardware Design (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14196662 | 2014-12-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3227277T true PT3227277T (pt) | 2020-04-14 |
Family
ID=52006914
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT158087700T PT3227277T (pt) | 2014-12-05 | 2015-12-04 | Composto antimicótico |
Country Status (18)
| Country | Link |
|---|---|
| US (12) | US10106531B2 (enExample) |
| EP (2) | EP3227277B1 (enExample) |
| JP (2) | JP6666345B2 (enExample) |
| KR (1) | KR102579848B1 (enExample) |
| CN (2) | CN107001343B (enExample) |
| AU (1) | AU2015356795B2 (enExample) |
| BR (1) | BR112017008481B1 (enExample) |
| CA (1) | CA2963625C (enExample) |
| DK (2) | DK3227277T3 (enExample) |
| EA (1) | EA033736B1 (enExample) |
| ES (2) | ES2790875T3 (enExample) |
| HU (2) | HUE048905T2 (enExample) |
| IL (1) | IL251631B (enExample) |
| MX (1) | MX370412B (enExample) |
| PL (1) | PL3227277T3 (enExample) |
| PT (1) | PT3227277T (enExample) |
| SG (1) | SG11201702835RA (enExample) |
| WO (2) | WO2016087880A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE048905T2 (hu) | 2014-12-05 | 2020-08-28 | Pulmocide Ltd | Antimikotikus vegyület |
| JP6694886B2 (ja) | 2014-12-18 | 2020-05-20 | プルモシデ リミテド | ４，５−ジヒドロ−６Ｈ−チエノ［３，２−ｄ］ベンゾアゼピン誘導体及び呼吸器合胞体ウイルス（ＲＳＶ）感染を治療するためのその使用 |
| JP6811727B2 (ja) | 2015-05-21 | 2021-01-20 | プルモシデ リミテド | 抗真菌性の４−（４−（４−（（（３ｒ，５ｒ）−５−（（１ｈ−１，２，４−トリアゾール−１−イル）メチル）−５−（２，４−ジフルオロフェニル）テトラヒドロフラン−３−イル）メトキシ）−３−メチルフェニル）ピペラジン−１−イル）−ｎ−（２−ヒドロキシシクロヘキシル）ベンズアミド、又はその医薬として許容し得る塩 |
| WO2017093491A1 (en) * | 2015-12-04 | 2017-06-08 | Pulmocide Limited | Antimycotic triazole compound |
| WO2018096405A1 (en) * | 2016-11-28 | 2018-05-31 | Cellix Bio Private Limited | Compositions and methods for the treatment of oral infectious diseases |
| WO2018115319A2 (en) | 2016-12-23 | 2018-06-28 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Inhibitors of cytochrome p450 family 7 subfamily b member 1 (cyp7b1) for use in treating diseases |
| GB201917867D0 (en) * | 2019-12-06 | 2020-01-22 | Pulmocide Ltd | Polymorphs |
| EP3858357A1 (en) * | 2020-01-28 | 2021-08-04 | Diaccurate | Use of azole compounds to stimulate the immune system and as inhibitors for s-pla2gib |
| RU2770598C1 (ru) * | 2021-06-29 | 2022-04-18 | Федеральное государственное автономное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" (ПГНИУ) | ПРИМЕНЕНИЕ ПРОТИВОГРИБКОВОГО СРЕДСТВА НА ОСНОВЕ 2-((4-R1-5-R2-3-(ЭТОКСИКАРБОНИЛ)ТИОФЕН-2-ИЛ)АМИНО)-4-ОКСО-4-R3-БУТ-2-ЕНОВЫХ КИСЛОТ ПО ОТНОШЕНИЮ К Candida aldicans |
| WO2025114603A1 (en) | 2023-11-30 | 2025-06-05 | Basilea Pharmaceutica International Ag, Allschwil | Pharmaceutical combinations for use in the treatment of fungal infections |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5533466A (en) * | 1978-07-14 | 1980-03-08 | Janssen Pharmaceutica Nv | Novel azole derivatives and their manufacture |
| CH655103A5 (de) * | 1983-03-11 | 1986-03-27 | Sandoz Ag | Azolderivate, verfahren zu ihrer herstellung und ihre verwendung. |
| CA1292472C (en) | 1985-12-03 | 1991-11-26 | Alfonsus Guilielmus Knaeps | Derivatives of ¬¬4-¬4-(4-phenyl-1-piperazinyl)- phenoxymethyl|-1,3-dioxolan-2-yl|methyl|-1h-imidazoles and 1h-1,2,4-triazoles |
| DE3609598A1 (de) * | 1986-03-21 | 1987-10-01 | Hoechst Ag | 2-azolylmethyl-2-aryl-1,3-dioxolane und deren salze, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung |
| JPH0717634B2 (ja) | 1987-11-20 | 1995-03-01 | シェリング・コーポレーション | トリ‐およびテトラ‐置換‐オキセタンおよびテトラヒドロフランおよびその中間体 |
| US5039678A (en) | 1989-03-23 | 1991-08-13 | Wake Forest University | Method of increasing cranial vessel proliferation by administering nimodipine |
| US5039676A (en) | 1990-05-11 | 1991-08-13 | Schering Corporation | Tri- and tetra-substituted-oxetanes and tetrahydrofurans and intermediates thereof |
| US5403937A (en) * | 1993-04-30 | 1995-04-04 | Schering Corporation | Process for preparing intermediates for the synthesis of antifungal agents |
| US5714490A (en) | 1993-12-21 | 1998-02-03 | Schering Corporation | Tetrahydrofuran antifungals |
| AU681753B2 (en) | 1993-12-21 | 1997-09-04 | Merck Sharp & Dohme Corp. | Tetrahydrofuran antifungals |
| US5486625A (en) | 1994-07-08 | 1996-01-23 | Schering Corporation | Process for the preparation of chiral intermediates useful for the synthesis of antifungal agents |
| IL118464A (en) | 1995-06-02 | 2000-08-13 | Schering Corp | (2R-cis)-4-¬4-¬4-¬4¬¬-5-(2',4 dihalophenyl)-tetrahydro-5-(1-H-1,2,4,triazol-1-yl-methyl)furan-3-yl(methoxy¾phenyl¾-1-piperazinyl¬phenyl2,4,dihydro2¬(5)-1-ethyl-2-(5)hydroxy propyl¾-3H-1,2,4-triazol-3-one and pharmaceutical compositions comprising them |
| EP0957101A1 (en) | 1998-05-14 | 1999-11-17 | Janssen Pharmaceutica N.V. | Water soluble azoles as broad-spectrum antifungals |
| EP2090165A3 (en) | 2001-04-03 | 2012-03-28 | Schering Corporation | Antifungal composition with enhanced bioavailability |
| CA2709784A1 (en) * | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| US8324385B2 (en) * | 2008-10-30 | 2012-12-04 | Madrigal Pharmaceuticals, Inc. | Diacylglycerol acyltransferase inhibitors |
| ES2649995T3 (es) * | 2011-07-18 | 2018-01-16 | Merck Patent Gmbh | Benzamidas |
| WO2013036866A1 (en) | 2011-09-07 | 2013-03-14 | The Johns Hopkins University | Itraconazole analogs and use thereof |
| HUE048905T2 (hu) | 2014-12-05 | 2020-08-28 | Pulmocide Ltd | Antimikotikus vegyület |
| GB201917867D0 (en) | 2019-12-06 | 2020-01-22 | Pulmocide Ltd | Polymorphs |
-
2015
- 2015-12-04 HU HUE15808770A patent/HUE048905T2/hu unknown
- 2015-12-04 ES ES15808770T patent/ES2790875T3/es active Active
- 2015-12-04 WO PCT/GB2015/053733 patent/WO2016087880A1/en not_active Ceased
- 2015-12-04 DK DK15808770.0T patent/DK3227277T3/da active
- 2015-12-04 JP JP2017528789A patent/JP6666345B2/ja active Active
- 2015-12-04 SG SG11201702835RA patent/SG11201702835RA/en unknown
- 2015-12-04 US US15/524,505 patent/US10106531B2/en active Active
- 2015-12-04 PL PL15808770T patent/PL3227277T3/pl unknown
- 2015-12-04 PT PT158087700T patent/PT3227277T/pt unknown
- 2015-12-04 CN CN201580066092.6A patent/CN107001343B/zh active Active
- 2015-12-04 EP EP15808770.0A patent/EP3227277B1/en active Active
- 2015-12-04 MX MX2017007188A patent/MX370412B/es active IP Right Grant
- 2015-12-04 EP EP15817507.5A patent/EP3227278B1/en active Active
- 2015-12-04 CA CA2963625A patent/CA2963625C/en active Active
- 2015-12-04 DK DK15817507.5T patent/DK3227278T3/da active
- 2015-12-04 KR KR1020177013730A patent/KR102579848B1/ko active Active
- 2015-12-04 EA EA201791174A patent/EA033736B1/ru not_active IP Right Cessation
- 2015-12-04 HU HUE15817507A patent/HUE048685T2/hu unknown
- 2015-12-04 ES ES15817507T patent/ES2786374T3/es active Active
- 2015-12-04 BR BR112017008481-3A patent/BR112017008481B1/pt active IP Right Grant
- 2015-12-04 WO PCT/GB2015/053731 patent/WO2016087878A1/en not_active Ceased
- 2015-12-04 JP JP2017528775A patent/JP6669751B2/ja active Active
- 2015-12-04 AU AU2015356795A patent/AU2015356795B2/en active Active
- 2015-12-04 CN CN202011308132.2A patent/CN112375073B/zh active Active
-
2016
- 2016-10-20 US US15/298,431 patent/US10093659B2/en active Active
-
2017
- 2017-04-06 IL IL251631A patent/IL251631B/en active IP Right Grant
-
2018
- 2018-09-12 US US16/129,322 patent/US10487073B2/en active Active
- 2018-09-24 US US16/139,591 patent/US10344022B2/en active Active
-
2019
- 2019-05-24 US US16/422,062 patent/US10450304B2/en active Active
- 2019-09-12 US US16/569,128 patent/US10662179B2/en active Active
- 2019-10-04 US US16/593,444 patent/US10800762B2/en active Active
-
2020
- 2020-04-15 US US16/849,476 patent/US10858345B2/en active Active
- 2020-09-04 US US17/012,685 patent/US11008307B2/en active Active
- 2020-11-04 US US17/089,441 patent/US11661415B2/en active Active
-
2021
- 2021-04-14 US US17/230,009 patent/US20210238169A1/en not_active Abandoned
-
2023
- 2023-04-18 US US18/302,557 patent/US12269814B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI3134402T1 (sl) | 4-amino-imidazokinolinske spojine | |
| AP2017009836A0 (en) | Aminopyridyloxypyrazole compounds | |
| GB201417002D0 (en) | Novel compound | |
| GB201416186D0 (en) | Compounds | |
| GB201402431D0 (en) | Compounds | |
| IL251631B (en) | Antifungal compound | |
| GB201404987D0 (en) | Compounds | |
| GB201413695D0 (en) | Compound | |
| IL258952B (en) | A pyranodipyridine compound | |
| GB201521524D0 (en) | Compound | |
| AP2017009778A0 (en) | Azetidinyloxyphenylpyrrolidine compounds | |
| GB201412238D0 (en) | Compound | |
| GB201504956D0 (en) | Compounds | |
| GB201407694D0 (en) | Compound | |
| GB201407506D0 (en) | Novel compound | |
| GB201518950D0 (en) | Compound | |
| GB201418709D0 (en) | Compound | |
| GB201407693D0 (en) | Compound | |
| GB201405361D0 (en) | Compounds | |
| ZA201801098B (en) | Tetrahydrooxepinopyridine compound | |
| GB201413698D0 (en) | Compound | |
| GB201520391D0 (en) | Compound | |
| GB201520393D0 (en) | Compound | |
| GB201520189D0 (en) | Compound for use | |
| GB201403491D0 (en) | New compound |